Literature DB >> 17245804

Application of lag-time into exposure definitions to control for protopathic bias.

H Tamim1, A A Tahami Monfared, J LeLorier.   

Abstract

PURPOSE: To control for protopathic bias, some studies have incorporated the concept of lag-time into their exposure definition (time period before the index date that was not considered in assessing exposure). The objective of this study was to introduce a procedure to identify the best lag-time to be applied in studies where control for protopathic bias is required.
METHODS: We used data from a case-control study carried out to assess the association between exposure to proton pump inhibitors (PPIs) and risk of gastric cancer, using RAMQ databases. Exposure was defined as the number of defined daily doses of PPIs dispensed during the 5-year period prior to the index date (divided into four quartiles). Thirty-one different lag-times were applied (0-30 months) based on 1-month intervals. Logistic regression was used to estimate the matched odds ratio (OR) for each lag-time. The change point in the ln(ORs) was identified by applying a two-compartmental model and a segmented regression model.
RESULTS: A trend of decreasing ORs was found with the application of an increasing lag-time. As an illustration, the ORs for the 1st quartile of defined daily doses, when applying the 31 different lag-times, ranged between 3.52 when applying a 0 lag-time and 0.97 when applying a 30 months lag-time. Applying the two methods for the different lag-times showed that the ORs stabilized at around 6 months.
CONCLUSION: For the purpose of controlling for protopathic bias in pharmacoepidemiological studies, we have provided a method to assess the most appropriate lag-time that should be applied for the assessment of drug exposure. (c) 2007 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17245804     DOI: 10.1002/pds.1360

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  48 in total

1.  Risk of cancer in patients exposed to gabapentin in two electronic medical record systems.

Authors:  Michael C Irizarry; David J Webb; Nada Boudiaf; John Logie; Laurel A Habel; Natalia Udaltsova; Gary D Friedman
Journal:  Pharmacoepidemiol Drug Saf       Date:  2011-12-06       Impact factor: 2.890

2.  Examining the utilization and tolerability of the non-sedating antihistamine levocetirizine in England using prescription-event monitoring data.

Authors:  Deborah Layton; Vicki Osborne; Anna Gilchrist; Saad A W Shakir
Journal:  Drug Saf       Date:  2011-12-01       Impact factor: 5.606

3.  Association between use of acid-suppressive drugs and risk of gastric cancer. A nested case-control study.

Authors:  Hani Tamim; André Duranceau; Long-Qi Chen; Jacques Lelorier
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

4.  Flexible Modeling of the Association Between Cumulative Exposure to Low-Dose Ionizing Radiation From Cardiac Procedures and Risk of Cancer in Adults With Congenital Heart Disease.

Authors:  Coraline Danieli; Sarah Cohen; Aihua Liu; Louise Pilote; Liming Guo; Marie-Eve Beauchamp; Ariane J Marelli; Michal Abrahamowicz
Journal:  Am J Epidemiol       Date:  2019-08-01       Impact factor: 4.897

5.  Protopathic bias in observational studies on statin effectiveness.

Authors:  Maarit Jaana Korhonen; Risto Huupponen; Päivi Ruokoniemi; Arja Helin-Salmivaara
Journal:  Eur J Clin Pharmacol       Date:  2009-07-22       Impact factor: 2.953

6.  Indication bias or protopathic bias?

Authors:  Jean-Luc Faillie
Journal:  Br J Clin Pharmacol       Date:  2015-09-16       Impact factor: 4.335

7.  Association of Statin Use with Increased Risk of Musculoskeletal Conditions: A Retrospective Cohort Study.

Authors:  Una E Makris; Carlos A Alvarez; Eric M Mortensen; Ishak A Mansi
Journal:  Drug Saf       Date:  2018-10       Impact factor: 5.606

Review 8.  A pathway to improved prospective observational post-authorization safety studies.

Authors:  Victor A Kiri
Journal:  Drug Saf       Date:  2012-09-01       Impact factor: 5.606

9.  Statin use and breast cancer survival: a nationwide cohort study in Scotland.

Authors:  Úna C Mc Menamin; Liam J Murray; Carmel M Hughes; Chris R Cardwell
Journal:  BMC Cancer       Date:  2016-08-04       Impact factor: 4.430

10.  The Uncertainty of the Association Between Proton Pump Inhibitor Use and the Risk of Dementia: Prescription Sequence Symmetry Analysis Using a Korean Healthcare Database Between 2002 and 2013.

Authors:  Sun-Kyeong Park; Yeon-Hee Baek; Nicole Pratt; Lisa Kalisch Ellett; Ju-Young Shin
Journal:  Drug Saf       Date:  2018-06       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.